Compare CFFN & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | SDGR |
|---|---|---|
| Founded | 1893 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2010 | 2020 |
| Metric | CFFN | SDGR |
|---|---|---|
| Price | $8.84 | $19.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $7.25 | ★ $21.00 |
| AVG Volume (30 Days) | 839.7K | ★ 999.0K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | 45.14 |
| EPS | ★ 0.51 | N/A |
| Revenue | $16,300,000.00 | ★ $255,869,000.00 |
| Revenue This Year | $20.16 | $0.76 |
| Revenue Next Year | $6.62 | $4.60 |
| P/E Ratio | $17.18 | ★ N/A |
| Revenue Growth | 6.54 | ★ 23.29 |
| 52 Week Low | $5.97 | $10.95 |
| 52 Week High | $9.26 | $23.02 |
| Indicator | CFFN | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 77.50 |
| Support Level | $8.28 | $17.26 |
| Resistance Level | $9.26 | $19.51 |
| Average True Range (ATR) | 0.21 | 0.77 |
| MACD | -0.02 | 0.41 |
| Stochastic Oscillator | 61.27 | 95.25 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.